Synergistic effects could be achieved through the combination of AMG-176 with venetoclax in AML tumor models and in primary patient samples at a tolerated dose, highlighting the potential for dual MCL1 and BCL2 inhibition [129]. Here, MCL1 is linked to acute myeloid leukemia.